Basal cell carcinoma - Karsinoma Sela Basal
☆ Tamin'ny valin'ny Stiftung Warentest 2022 avy any Alemaina, ny fahafaham-pon'ny mpanjifa amin'ny ModelDerm dia ambany kely noho ny fifampidinihana telemedicine karama.
Loza misy moka miantraika amin'ny hoditry ny orona amin'ny olona be taona dia fantatra fa Karsinoma Sela Basal (Basal cell carcinoma). Ny orona dia toerana fahita matetika amin'ity karazana homamiadan'ny hoditra ity.
Karsinoma Sela Basal (Basal cell carcinoma) dia mety misy sisin-tany tsy ara-dalàna sy fery.
Karsinoma Sela Basal (Basal cell carcinoma) dia mety ho diso amin'ny ady.
References
Basal cell carcinoma (BCC) no karazana homamiadan'ny hoditra mahazatra indrindra. Ny tara-masoandro no tena antony. Saika ny tranga BCC rehetra dia mampiseho famantarana Hedgehog mahery vaika amin'ny famakafakana molekiola. Fitsaboana isan-karazany dia misy sy nofidina mifototra amin'ny risika miverimberina, ny maha-zava-dehibe ny fitehirizana ny sela, ny tian'ny marary ary ny halehiben'ny aretina.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas no karazana homamiadan'ny hoditra mahazatra indrindra amin'ny olon-dehibe 50 taona no ho miakatra. Mitombo ny isan'izy ireo maneran-tany, indrindra noho ny fiposahan'ny masoandro. Ny toe-piainana ara-pananahana sasany dia mety hahatonga ny olona ho mora voan'ny kansera amin'ny fahatanorany. Basal cell carcinomas dia miovaova amin'ny hamafin'ny aretina, manomboka amin'ny ratra mora tsaboina amin'ny maso na nodular ka hatrany amin'ny lehibe kokoa izay mitaky fifanakalozan-kevitra amin'ny ekipa mpitsabo manokana. Ny vinavina dia miankina amin'ny mety ho fiverenan'ny homamiadana na ny fahafahany manimba ny sela eo akaiky eo. Ny fandidiana no fomba fitsaboana mahazatra amin'ny ankamaroan'ny tranga, miantoka ny fanesorana marina sy ny mety hiverenan'izany. Ny fomba tsy dia misy invasive dia afaka mitsabo amin'ny fomba mahomby ny lesoka ambony.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Ny fitsaboana voalohany amin'ny BCC dia ny fandidiana. Ho an'ny BCC mampidi-doza na miverimberina, indrindra any amin'ny faritra saro-pady, dia asaina ny fandidiana mikrôgrafika. Ny marary manana BCC ambony ambany dia mety hihevitra ny fitsaboana amin'ny lohahevitra na fomba manimba. Ny fitsaboana photodynamic dia miasa tsara ho an'ny BCC nodular ambony sy ambany. Ho an'ny BCC efa mandroso na metastatika eo an-toerana, ny inhibitors Hedgehog (vismodegib, sonidegib) dia asaina. Raha misy ny fivoaran'ny aretina na ny tsy fandeferana amin'ny inhibitors Hedgehog dia azo raisina ny immunotherapy miaraka amin'ny anti-PD1 antibody (cemiplimab) . Ny radiotherapy dia safidy tsara ho an'ny marary tsy afaka fandidiana, indrindra ireo marary efa lehibe. Ny electrochemotherapy dia azo raisina raha toa ka tsy safidy ny fandidiana na radiotherapy.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Ny anton-javatra mety hampidi-doza dia ny fiposahan'ny taratra ultraviolet, ny fitsaboana amin'ny taratra, ny fiparitahan'ny arsenika maharitra ary ny fiasan'ny rafi-kery fanefitra (ohatra ny famindrana taova). Ny fiposahan'ny taratra UV mandritra ny fahazazana dia tena manimba.
Aorian'ny fitiliana amin'ny biopsy, ny fitsaboana dia matetika amin'ny fanesorana fandidiana. Izany dia azo atao amin'ny alalan'ny excision tsotra raha kely ny homamiadana; Raha tsy kely ny homamiadana, ny fandidiana Mohs dia asaina amin'ny ankapobeny.
Ny kanseran'ny sela basal dia mahatratra 32% farafahakeliny amin'ny homamiadana rehetra manerantany. Amin'ireo kanseran'ny hoditra ankoatra ny melanoma, manodidina ny 80% dia kanseran'ny sela basal. Any Etazonia, manodidina ny 35% amin'ny lahy fotsy sy 25% amin'ny vehivavy fotsy no voan'ny kanseran'ny sela basal amin'ny fotoana iray eo amin'ny fiainany.
○ Diagnose sy Fitsaboana
#Dermoscopy
#Skin biopsy
#Mohs surgery